Please review the QC test results indicated by icon below as well as clone information before placing your order.

pcDNA-DEST47-TOP2A

Gateway(R) expression vector of human TOP2A.

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Terms and conditions set forth by the DEPOSITOR	Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Katsushima, K et al. Nat. Commun. 7: 13616, 2016); (Deguchi, S et al. Oncogene. 36 (32) : 4629 - 4640, 2017) RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR.
Ordering	Please visit Information of Request for Distribution.[link]  Order form [Credit Card Payment]  [Bank Transfer or Check Payment] Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word] Schedule A (GFP-A) [Link] Approval form by depositor [Word]
Remarks	((Additional form)) Approval Form(FormD) Please use Schedule A (GFP-A) additionally. Please obtain written approval of the depositor. Gateway® Expression clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.

Distribution information (domestic users) [open/close]

提供条件	利用者は提供承諾書を用いて、事前に寄託者の承諾を得る。利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Katsushima, K et al. Nat. Commun. 7: 13616, 2016); (Deguchi, S et al. Oncogene. 36 (32) : 4629 - 4640, 2017)。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。
提供依頼	手続きの詳細は、「提供申込みについて[link]」をご覧ください。 提供依頼書 [Word] 提供同意書 (MTA、非営利機関による非営利学術研究用)[Word] Schedule A（GFP-A, 英語版のみ） [Link] 寄託者による提供承諾書 [Word]
備考	【追加提供依頼書】承諾書(FormD) Schedule A（GFP-A, 英語版のみ）が追加で必要です。 寄託者の書面による提供承諾が必要です。 Gateway®テクノロジーを用いた発現クローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Please review the QC test results indicated by icon below as well as clone information before placing your order.

References and tips

Electronic file

Original reference

Further references such as user reports and related articles (go to bottom)

Featured content

Sequence information

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.

Test sheet	RDB15801_A8Bqp1-1.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: CMV_Forward Region: CMV pro,attB1,insert 5' Sequence file: RDB15801_A8Bqa.seq
>D05196A8-6_A8Bq_CMV_Forward_E02_2018-03-19-14-24-28_14.ab1     1 CGTCAACTCC GCCCATTGAC GCAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA    61 GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG GCTTATCGAA ATTAATACGA   121 CTCACTATAG GGAGACCCAA GCTGGCTAGT TAAGCTTGAT CAAACAAGTT TGTACAAAAA   181 AGCAGGCTCC GCGGCCGCCC CCTTCACCAT GGAAGTGTCA CCATTGCAGC CTGTAAATGA   241 AAATATGCAA GTCAACAAAA TAAAGAAAAA TGAAGATGCT AAGAAAAGAC TGTCTGTTGA   301 AAGAATCTAT CAAAAGAAAA CACAATTGGA ACATATTTTG CTCCGCCCAG ACACCTACAT   361 TGGTTCTGTG GAATTAGTGA CCCAGCAAAT GTGGGTTTAC GATGAAGATG TTGGCATTAA   421 CTATAGGGAA GTCACTTTTG TTCCTGGTTT GTACAAAATC TTTGATGAGA TTCTAGTTAA   481 TGCTGCGGAC AACAAACAAA GGGACCCAAA AATGTCTTGT ATTAGAGTCA CAATTGATCC   541 GGAAAACAAT TTAATTAGTA TATGGAATAA TGGAAAAGGT ATTCCTGTTG TTGAACACAA   601 AGTTGAAAAG ATGTATGTCC CAGCTCTCAT ATTTGGACAG CTCCTAACTT CTAGTAACTA   661 TGATGATGAT GAAAAGAAAG TGACAGGTGG TCGAAATGGC TATGGAGCCA AATTGTGTAA   721 CATATTCAGT ACCAAATTTA CTGTGGAAAC AGCCAGTAGA GAATACAAGA AAATGTTCAA   781 ACAGACATGG ATGGATAATA TGGGAAGAGC TGGTGAGATG GAACTCAAGC CCTTCAATGG   841 AGAAGATTAT ACATGTATCA CCTTTCAGCC TGATTTGTCT AAGTTTAAAA TGCAAAGCCT   901 GGACAAAGAT ATTGTTGCAC TAATGGTCAG AAGAGCATAT GATATTGCTG GGATCCACCA   961 AAGATGTCAA AGTCTTTTCT TAATGGAAAT AAACTGCCAG TAAAAGGATT TCGTAGTTAT  1021 GTGGACATGT ATTTGGAAGG ACAAGTTGGG ATGGAACCTG CTTACTGTTG GAAGTATACA 1081 TGAACCAAGT TAAATGACAG GTGGGAAGGG TGGTG //
Primer: GFP-N_R Region: Cycle 3 GFP,attB2,insert 3' Sequence file: RDB15801_A8Bqb.seq
>D05196A8-6_A8Bq_GFP-N_R_F02_2018-03-19-14-24-28_17.ab1     1 TATTGGGGGG AAAACTCCAG TGAAAAGTTC TTCTCCTTTG CTAGCCATTC TAGATCGAAC    61 CACTTTGTAC AAGAAAGCTG GGTCGGCGCG CCCACCCTTT TAAAACAGAT CATCTTCATC   121 TGACTCTTCC AGGTACTTTA TAGGTTTCTT TGCCCGTACA GATTTTGCCC GAGGAGCCAC   181 AGCTGAGTCA AAGTCCATAT GGAAGTCATC ACTCTCCCCC TTGGATTTCT TGCTTGTGAC   241 TGCTTTCGAA ACAATTTTCT CAAAATTAGA GTCAGAATCA TCAGAAGTGG ATGGCTTCCT   301 TTTGCGGCGA TTCTTGGTTT TGGCAGGATC AGGCTTTTGA GAGACACCAG AATTCAAAGC   361 TGGATCCCTT TTAGTTCCTT TTGGGGCAGC CCTTTTTTTG GCACCGGTAG TGGAGGTGGA   421 AGACTGACTT TTTGCTGCTG TCTTCTTCAC TGTCACATTC TTTTTAGGAA CTGGGTTTGT   481 AATTTCAGTT TCATCTGGGA AATGTGTAGC AGGAGGGCTT GAAGACAGTG GTACACTGCC   541 CTTAACATCA TCAGCTTCAA GGTCTGACAC GACACTTTTC TGTGGTTTCA GTTCTTTGTT   601 ACTAAGTTTT GGGGAAGTTT TGGTCTTAGG TGGACTAGCA TCTGATGGGA CAAAATCTTC   661 ATCATCAGTT TTTTCATCAA AATCTGAGAA ATCTTCATCT GAATCCAAAT CCATTGTGAA   721 TTTTGTTTTT GTTGCTGCTC TCCGTGGCTC TGTTTCTCGT GGAGGGACAT CAAAATTACT   781 TTCGTCACTG CTCCTATCTG ATTCTGAATC AGACCAGGGA TTTCTCTTCT TTCCTTTTTT   841 TGATTGGCTT AAATGCCAAT GTAGTTTGTT TCTTTGTCTT TGTACCTGGT TCTCTTTTCT   901 GTTTCTTTTC TAATCTTTGT TTTAGGCCTT CTAGTTCCAC ACCATCTTTC TTGAGGGCTT   961 CCTTCAGTAT TTTCATTCTT AAATTTTCTT TTTTATTTTT TCTTTTCTGC CTCTGCTTTC  1021 ATTTCTATGA TATTTCGTGG AATGACTCTT TTGACCACGG CGAGGAAGCA AAACTTCAGA 1081 CATTTGTGTT TTTTTTTCCC ATTGGGACCG ATTCCCCCCC TTTGC //
Primer: BGH_rev2 Region: bGHpA,Cycle 3 GFP,attB2,insert 3' Sequence file: RDB15801_A8Bqc.seq
>D05196A8-6_A8Bq_BGH_rev2_G02_2018-03-19-14-24-28_20.ab1     1 CATCTAGGGC TAGGGGAAGG CACGGGGGAG GGGCAAACAA CAGATGGCTG GCAACTAGAA    61 GGCACAGTCG AGGCTGATCA GCGGGTTTAA TTCATTATTT GTAGAGCTCA TCCATGCCAT   121 GTGTAATCCC AGCAGCAGTT ACAAACTCAA GAAGGACCAT GTGGTCACGC TTTTCGTTGG   181 GATCTTTCGA AAGGGCAGAT TGTGTCGACA GGTAATGGTT GTCTGGTAAA AGGACAGGGC   241 CATCGCCAAT TGGAGTATTT TGTTGATAAT GGTCTGCTAG TTGAACGGAT CCATCTTCAA   301 TGTTGTGGCG AATTTTGAAG TTAGCTTTGA TTCCATTCTT TTGTTTGTCT GCCGTGATGT   361 ATACATTGTG TGAGTTATAG TTGTACTCGA GTTTGTGTCC GAGAATGTTT CCATCTTCTT   421 TAAAATCAAT ACCTTTTAAC TCGATACGAT TAACAAGGGT ATCACCTTCA AACTTGACTT   481 CAGCACGCGT CTTGTAGTTC CCGTCATCTT TGAAAGATAT AGTGCGTTCC TGTACATAAC   541 CTTCGGGCAT GGCACTCTTG AAAAAGTCAT GCCGTTTCAT ATGATCCGGA TAACGGGAAA   601 AGCATTGAAC ACCATAAGAG AAAGTAGTGA CAAGTGTTGG CCATGGAACA GGTAGTTTTC   661 CAGTAGTGCA AATAAATTTA AGGGTAAGCT TTCCGTATGT AGCATCACCT TCACCCTCTC   721 CACTGACAGA AAATTTGTGC CCATTAACAT CACCATCTAA TTCAACAAGA ATTGGGACAA   781 CTCCAGTGAA AAGTTCTTCT CCTTTGCTAG CCATTCTAGA TCGAACCACT TTGTACAAGA   841 AAGCTGGGTC GGCGCGCCCA CCCTTTTAAA ACAGATCATC TTCATCTGAC TCTTCCAGGT   901 ACTTTATAGG TTTCTTTGCC CGTACAGATT TTGCCCGAGG AGCCACAGCT GAGTCAAAGT   961 CCATATGGGA AGTCATCACT CTCCCCCCTT TGGATTTCTT TGCTTGTGAC TGCTTTCGAA  1021 CAATTTTCTC AAAATTAGAG GTCAGATCAT CAGAAGTGGG ATGGCTTCGT TTTTGGCGCG 1081 ATTCTTGGTT TGCAGATCAG GCTTTTTGAG AAGAACACCA GAATTCAAAG CTGTGATTC //
Primer: SV40pro_F Region: SV40 pro_ori,NeoR Sequence file: RDB15801_A8Bqd.seq
>D05196A8-6_A8Bq_SV40pro_F_H02_2018-03-19-14-24-28_23.ab1     1 ACTCGGTCCC GTAACATTCA GAAGGTAGTG AGGAGGCTTT TTTGGAGGCC TAGGCTTTTG    61 CAAAAAGCTC CCGGGAGCTT GTATATCCAT TTTCGGATCT GATCAAGAGA CAGGATGAGG   121 ATCGTTTCGC ATGATTGAAC AAGATGGATT GCACGCAGGT TCTCCGGCCG CTTGGGTGGA   181 GAGGCTATTC GGCTATGACT GGGCACAACA GACAATCGGC TGCTCTGATG CCGCCGTGTT   241 CCGGCTGTCA GCGCAGGGGC GCCCGGTTCT TTTTGTCAAG ACCGACCTGT CCGGTGCCCT   301 GAATGAACTG CAGGACGAGG CAGCGCGGCT ATCGTGGCTG GCCACGACGG GCGTTCCTTG   361 CGCAGCTGTG CTCGACGTTG TCACTGAAGC GGGAAGGGAC TGGCTGCTAT TGGGCGAAGT   421 GCCGGGGCAG GATCTCCTGT CATCTCACCT TGCTCCTGCC GAGAAAGTAT CCATCATGGC   481 TGATGCAATG CGGCGGCTGC ATACGCTTGA TCCGGCTACC TGCCCATTCG ACCACCAAGC   541 GAAACATCGC ATCGAGCGAG CACGTACTCG GATGGAAGCC GGTCTTGTCG ATCAGGATGA   601 TCTGGACGAA GAGCATCAGG GGCTCGCGCC AGCCGAACTG TTCGCCAGGC TCAAGGCGCG   661 CATGCCCGAC GGCGAGGATC TCGTCGTGAC CCATGGCGAT GCCTGCTTGC CGAATATCAT   721 GGTGGAAAAT GGCCGCTTTT CTGGATTCAT CGACTGTGGC CGGCTGGGTG TGGCGGACCG   781 CTATCAGGAC ATAGCGTTGG CTACCCGTGA TATTGCTGAA GAGCTTGGCG GCGAATGGGC   841 TGACCGCTTC CTCGTGCTTT ACGGTATCGC CGCTCCCGAT TCGCAGCGCA TCGCCTTCTA   901 TCGCCTTCTT GACGAGTTCT TCTGAGCGGG ACTCTGGGGG TTCGCGAAAT GACCGACCCA   961 AGCGACGCCC AACCCTGCCC ATCACGAGAT TTCGATTCCC ACCCGCGCCT TTCTATGAAA  1021 GGTTGGGCTT TCGGAATTCG TTTTCCGGGA CGCCGGCTGG ATGAATCTTC AGCGCGGGAT 1081 CTCATGCTGA GTCATCGCCA CCCGACTGTT ATTGCCAGCC TTA //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

2020.10.15

GNP_filter3_RDBDEP_html_200316.pl